- Q1. What is the business of Molbio Diagnostics Limited ?It is an Indian molecular diagnostics firm that makes Truenat point-of-care PCR devices and test kits for rapid detection of infectious diseases like TB, COVID-19, HIV and more.
- Q2. Why is the company raising funds via IPO?Molbio Technologies is raising funds via IPO to raise capital for R&D facilities, a Centre of Excellence, and machinery upgrades for its manufacturing units, plus general corporate use.
- Q3. What is the size of the issue and where will it list?The issue size of the IPO comprises of ₹ 200 Cr as Fresh Issue + OFS ~1.26 Cr equity shares. It will be listed on BSE and NSE platform.
- Q4. What are the key risks to an investor?Key risks include high dependence on public healthcare/government contracts, customer concentration, and reliance on TB test revenues.
- Q5. What are the potential upsides?Upsides include strong global adoption of Truenat tech, recurring test kit sales, solid revenue growth and WHO recognition for key tests.
- Q6. How to apply for the IPO?Investors can apply for the IPO through ASBA via net banking or using UPI through registered stock brokers once the IPO opens for subscription.
Closed
Molbio Diagnostics Limited
0
IPO Score
0
*Score varies on actual price
Molbio Diagnostics Limited is an Indian medical diagnostics company that develops and manufactures point-of-care molecular diagnostic technologies, including its flagship Truenat platform – a portable, battery-operated PCR system used to deliver rapid test results (within about an hour) for infectious diseases such as tuberculosis (TB), COVID-19, HIV, HPV, and hepatitis B & C. It operates multiple manufacturing facilities in India and serves both domestic and international markets.
Molbio Diagnostics has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) for an IPO consisting of a Fresh Issue of ₹ 200 Crore and an Offer-for-Sale (OFS) of ₹ 740 Crore (12,556,000 Equity Shares by existing shareholders).
Molbio Diagnostics Limited opens for subscription on 10th August & closes on 12th August. Price band for the IPO is ₹768 – ₹807 with a lot size of 18 Shares.
It was incorporated in 2000 & currently Mr. Sriram Natarajan serves as the Executive Director & Chief Executive Officer (CEO) of the company.
Molbio Diagnostics is the Truenat point-of-care molecular diagnosis platform – a portable, battery-operated PCR system that provides rapid testing for infectious and selected non-communicable diseases. It has exported its Truenat platform to over 85 countries with over ~10,000 installations globally and has empowered diagnostics for 40 + million individuals.
Revenue, PAT, EBITDA
Year |
2025 |
|---|---|
Networth
|
₹ 952.94 Cr
|
Revenue
|
₹ 1020.41 Cr
|
EBITDA
|
₹ 256.63 Cr
|
PAT
|
₹ 138.57 Cr
|
EBITDA Margin
|
24.97%
|
PAT Margin
|
13.48%
|
Face Value
|
Rs.01 per Equity Share
|
IPO Important Dates
# |
Date |
|---|---|
Open Date
|
10-Aug
|
Close Date
|
12-Aug
|
Anchor Investor Bidding
|
09-Aug
|
Allotment Date
|
13-Aug
|
Refunds& Demat Credit
|
14-Aug
|
Tentative Listing Date
|
17-Aug
|
Use Of Proceeds
Purpose |
Amount |
|---|---|
Technology & Infrastructure
|
₹ 99.36 Cr
|
Purchasing Plant & Machinery
|
₹ 73.59 Cr
|
-
|
-
|
-
|
-
|
-
|
-
|
General Corporate Purpose
|
Balance
|
Financial Data
# |
2023 |
2024 |
2025 |
|---|---|---|---|
Revenue (₹ Cr)
|
₹ 332.5
|
₹ 836.6
|
₹ 1,020.4
|
PAT (₹ Cr)
|
₹ -3.4
|
₹ 83.5
|
₹ 138.6
|
Asset (₹ Cr)
|
₹ 1,034.2
|
₹ 1,221.1
|
₹ 1,461.6
|
Net Worth (₹ Cr)
|
₹ 706.0
|
₹ 807.9
|
₹ 952.9
|
IPO Grey Market Premium
Date |
IPO Price |
IPO GMP |
Profit Per Lot |
|---|---|---|---|
12-Aug
|
₹768 – ₹807
|
₹ 152
|
₹ 2,736
|
11-Aug
|
₹768 – ₹807
|
₹ 140
|
₹ 2,520
|
10-Aug
|
₹768 – ₹807
|
₹ 132
|
₹ 2,376
|
09-Aug
|
₹768 – ₹807
|
₹ 140
|
₹ 2,520
|
08-Aug
|
₹768 – ₹807
|
₹ 180
|
₹ 3,240
|
Promoters – Pre offer equity (Approx)
Promoters |
% Shares |
|---|---|
Exxora Trading LLP
|
41.23 %
|
Dr. Chandrasekhar Bhaskaran Nair
|
5.42 %
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Lot Size details
Application Type |
Lot Size |
No. of Lot |
No. of Shares |
Investment Amount |
|---|---|---|---|---|
Retail (Min)
|
18 Shares
|
1
|
18
|
₹ 14,526
|
Retail (Max)
|
18 Shares
|
13
|
234
|
₹ 1,88,838
|
HNI (Min)
|
18 Shares
|
14
|
252
|
₹ 2,03,364
|
HNI (Max)
|
18 Shares
|
66
|
1,188
|
₹ 9,58,716
|
Big HNI (Min)
|
18 Shares
|
67
|
1,206
|
₹ 9,73,242
|
Key Performance Index (KPI)
ROE |
16.20% |
|---|---|
ROCE
|
20.98%
|
RoNW
|
15.23%
|
JOIN OUR SOCIAL-MEDIA PLATFORMS TO STAY UPDATED
Checkout more upcoming IPO's
Travelstack Tech Limited
Travelstack Tech Limited (formerly Casa2 Stays Private Limited) is the parent company of the prominent...
Read More
TKW Supply Chain International Limited
TKW Supply Chain International Limited is a New Delhi-based third-party logistics (3PL) provider offering integrated...
Read More
Casagrand Premier Builder Limited
Casagrand Premier Builder Limited is a leading Chennai-based real estate developer with a dominant 24%...
Read More
Surgiwear Limited
G. Surgiwear Limited manufactures medical devices and surgical products, including orthopaedic implants, hydrocephalus shunts, cranial...
Read More
GENXAI ANALYTICS LIMITED
Genxai Analytics Limited is a technology-focused enterprise specializing in advanced AI-driven solutions and enterprise performance...
Read More